OOIR: Observatory of International Research

Papers

(The H4-Index of Translational Neurodegeneration is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	316
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	283
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	179
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	168
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	139
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	108
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	105
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	88
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	86
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	81
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	80
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	80
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	79
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	77
Role of dopamine in the pathophysiology of Parkinson’s disease	70
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	69
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	65
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	64
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	63
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	63
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	61
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	58
NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity	56
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	56
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	54

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta	52
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	52
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	52
Inflammasomes in neurodegenerative diseases	50
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	47
Nose-to-brain drug delivery: from bench to bedside	46
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	45
Peripheral proteinopathy in neurodegenerative diseases	45
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	45
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	43
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	43
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	42
Multidimensional biomarkers for multiple system atrophy: an update and future directions	41
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	41
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	41
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	40
Mitochondrial links between brain aging and Alzheimer’s disease	40